Your new post is loading...
In recent years, significant progress has been made in the use of monoclonal antibodies in the treatment of systemic lupus erythematosus (SLE). Advances in our understanding of the complexity of SLE immunopathogenesis have led to the testing of several biologic agents in clinical trials. Monoclonal therapies currently emerging or under development include B-cell depletion therapies, agents targeting B-cell survival factors, blockade of T-cell co-stimulation and anticytokine therapies. Issues remain, however, regarding clinical trial design and outcome measures in SLE which need to be addressed to optimize translation of these promising therapies into clinical practice.
Via Krishan Maggon
ReviewProgress with the use of monoclonal antibodies for the treatment of systemic lupus erythematosusNatasha Jordan‡,1, Pamela MK Lutalo‡,1,2 & David P D’Cruz*,1*Author for correspondence: david.d'cruz@kcl.ac.uk